Fore Biotherapeutics
Lately:2 news stories in 90 daysFollow changes →
Facts
as of Nov 17, 2026Leading the future of targeted therapies for the hardest to treat cancers. Wednesday, October 15, 202512:00 pm ET.
- Employees
- 51-200estimated range
- Website
- fore.bio
These are the key facts about Fore Biotherapeutics on Alion as of Nov 17, 2026. It has raised $105.4M in 2 funding rounds. The latest round is Series D of $67.4M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Financials
Funding rounds, investors and revenue on record.
$105.4MTotal raised
Series DLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
2026
$67.4M
$38M
Sources: funding announcements, grant and company registers
Milestones
Jul 6
Raised a round Series D $67.4M
May 22, 2025
Raised a round Venture round $38M
Aug 11, 2024
Feb 2021
Website went live first capture in the Wayback Machine
Each milestone is dated by its source: registers, filings, the press
Newsroom
Jul 102026
News · Pulse 2.0
FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing…
Jul 72026
Sources: the outlets named on each headline, each story once
